Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong Y, Qin JX, Wang GY, Zhang XM, Xia T, Liang Q, Zhao Y, Li R, Zhang SQ, Zhang JH, Chen JG, Wang GC, Chen ZS, Han CH.
Shi ZD, et al. Among authors: liang q.
Mol Cancer. 2022 Feb 7;21(1):37. doi: 10.1186/s12943-022-01517-9.
Mol Cancer. 2022.
PMID: 35130920
Free PMC article.